{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Disease-Modifying+Therapies+%28DMTs%29",
    "query": {
      "intervention": "Disease-Modifying Therapies (DMTs)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 15,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Disease-Modifying+Therapies+%28DMTs%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T15:21:39.957Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03399981",
      "title": "Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Progressive Multifocal Leukoencephalopathy"
      ],
      "interventions": [
        {
          "name": "Tysabri",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 80327,
      "start_date": "2017-06-01",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-03-19",
      "last_synced_at": "2026-10-02T15:21:39.957Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03399981"
    },
    {
      "nct_id": "NCT05658497",
      "title": "Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Diroximel Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Avonex",
          "type": "DRUG"
        },
        {
          "name": "Tysabri",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dimethyl Fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 908,
      "start_date": "2023-10-27",
      "completion_date": "2032-07-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-02T15:21:39.957Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Durham, North Carolina",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05658497"
    },
    {
      "nct_id": "NCT05319093",
      "title": "Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fatigue",
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ozanimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2022-04-01",
      "completion_date": "2024-07-23",
      "has_results": false,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-10-02T15:21:39.957Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05319093"
    },
    {
      "nct_id": "NCT04956744",
      "title": "A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "IMS001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ImStem Biotechnology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-08-31",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-10-02T15:21:39.957Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Worcester, Massachusetts • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04956744"
    },
    {
      "nct_id": "NCT04754542",
      "title": "Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS): Extension of the DISCOMS Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2021-05-18",
      "completion_date": "2022-11-30",
      "has_results": true,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-10-02T15:21:39.957Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • Kansas City, Kansas • New York, New York + 6 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04754542"
    },
    {
      "nct_id": "NCT04387734",
      "title": "Effects of Ocrevus in Relapsing Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "Platform",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgia State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2021-02-05",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-02T15:21:39.957Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04387734"
    },
    {
      "nct_id": "NCT01216072",
      "title": "A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Relapsing Forms of Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Fingolimod",
          "type": "DRUG"
        },
        {
          "name": "Standard MS DMTs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1053,
      "start_date": "2010-08",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-02-10",
      "last_synced_at": "2026-10-02T15:21:39.957Z",
      "location_count": 142,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01216072"
    },
    {
      "nct_id": "NCT03222973",
      "title": "Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "BIIB033 (opicinumab)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "58 Years",
        "sex": "ALL",
        "summary": "18 Years to 58 Years"
      },
      "enrollment_count": 263,
      "start_date": "2017-11-15",
      "completion_date": "2021-02-12",
      "has_results": true,
      "last_update_posted_date": "2022-04-28",
      "last_synced_at": "2026-10-02T15:21:39.957Z",
      "location_count": 51,
      "location_summary": "Cullman, Alabama • Gilbert, Arizona • Berkeley, California + 44 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03222973"
    },
    {
      "nct_id": "NCT05528666",
      "title": "Risk Perception in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "High Efficacy Therapy (HET)",
          "type": "OTHER"
        },
        {
          "name": "Non High Efficacy Therapy (Non-HET)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 4361,
      "start_date": "2021-09-09",
      "completion_date": "2021-09-17",
      "has_results": false,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-10-02T15:21:39.957Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05528666"
    },
    {
      "nct_id": "NCT05605782",
      "title": "A Post-Authorization, Long-term Study of Ozanimod Real-world Safety",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9000,
      "start_date": "2021-09-02",
      "completion_date": "2033-07-26",
      "has_results": false,
      "last_update_posted_date": "2025-06-26",
      "last_synced_at": "2026-10-02T15:21:39.957Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05605782"
    }
  ]
}